PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations - Cancer Treatment Reviews
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial - Gynecologic Oncology
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian... | OncologyPRO
PAOLA-1 Trial
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer | SpringerLink
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Adverse Reactions and Tolerability for LYNPARZA® (olaparib) in PAOLA-1
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer - PMLiVE
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
ESMO | Press Release | Ovarian Cancer Olaparib PAOLA1 Ray Coquard
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - ScienceDirect
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Olaparib Plus Bevacizumab Combination Expands Options in HRD+ Cancer
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial - ScienceDirect
PAOLA-1 Phase 3 Trial – LYNPARZA® (olaparib) + Bevacizumab for Advanced Ovarian Cancer
